Skip to content
GLP321News
- Jul 8, 2026A Dietitian's Guide to Protein Snacks for GLP-1 Users
On GLP-1 medications, appetite drops sharply, and dietitians say protein-dense snacks are one practical way to keep protein intake up while meals feel harder to finish. - Jul 3, 2026GLP321 is live.
Happy 4th of July. - Jun 25, 2026Medicare's GLP-1 Bridge program covers Foundayo and Zepbound at $50 a month
Eli Lilly says eligible Medicare Part D patients can get the Foundayo pill or Zepbound injection for weight management at $50 a month, starting July 1, 2026. - Jun 11, 2026Semaglutide slowed biological aging markers in an early UC San Diego trial
Researchers report the first randomized, placebo-controlled evidence that the GLP-1 drug semaglutide slowed several markers of biological aging over 32 weeks. - May 22, 2026NIH researchers identify avenue for enhanced GLP-1-induced weight loss
Modulating intracellular signaling may extend drug effects. - Apr 1, 2026FDA approves Lilly's Foundayo, the first GLP-1 pill with no food or water restrictions
The FDA approved Eli Lilly's once-daily orforglipron (Foundayo), the first GLP-1 pill that can be taken any time of day, for adults with obesity or overweight and a related condition. - Mar 12, 2026What happens after patients stop GLP-1 drugs? A real-world Cleveland Clinic study
An analysis of nearly 8,000 patients found that most avoided major weight regain after a year, often by restarting the drug or moving to another treatment.